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Executive Summary 
 
During the last two presidential elections, embryonic stem cells (ESCs) have been a major issue that 
voters have had to consider. In anticipation of it continuing to be a significant issue in the 2008 
presidential election, this project’s purpose was to explain the basic biology of ESCs, how they relate to 
the political and ethical issues surrounding their use, and the misconceptions that make it necessary to 
explain them more clearly. 
An overview of the basic biology is provided to allow voters to examine the political debates more 
thoroughly and develop their own opinions. Alternatives to ESCs are also explained such as induced 
pluripotent stem cells, multipotent adult progenitor cells, and hematopoietic stem cells, although some 
of these alternatives may present drawbacks such as being tumorigenic. Since the political debate is 
mostly based upon ethics, voters should know the facts to apply them to their own ethical standards, 
not just those of each political party. With voters able to decide their stance on the stem cell issue, they 
will also be able to choose a candidate that best fits their views on this specific issue. The traditional 
stances of the major political parties cannot be applied to their respective candidates in this presidential 
election. In researching voting records of each presidential candidate, it was found that of the bills that 
have passed through the Senate, both Senator McCain and Senator Obama share a similar stance. Each 
supports funding for ESC research with limited ethical clauses such as no monetary gain and necessity of 
consent from donors. This is one of the most important findings in our research, since it significantly 
limited the potential of a focus point for voters to decide upon a candidate. 
Knowing the background of stem cells helps only if it can be applied to the advancements of the issue. 
To allow voters to accurately interpret the media’s reports on stem cell developments, reports were 
analyzed and compared to scientific journal reports on the same issues. While the media can deliver 
valuable information, it acts as a filter for medical journals and delivers only certain information. Stories 
are frequently embellished and make promises which have not come to fruition to date. This analysis 
allows voters to keep track of the debate through easily accessible and widely distributed forms of 
media such as newspapers without having the facts become skewed by the way a newspaper presents 
them. 
The end result of this project is the simplification of the ESC debate for voters to quickly become 
educated and decide which candidate best fits their stance on the issue of ESCs in the 2008 presidential 
election. 
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Introduction 
 
“Stem cells” is a household phrase and people around the world are continuing to gain awareness both 
of the potential scientific achievements and the moral disputes associated with the research. The 
potential use of embryonic stem cells (ESCs) to treat many diseases is extremely attractive, but the cost 
of destroying embryos may be too large of a moral price for many Americans to pay. As the presidential 
elections near, it is important for voters to understand the realistic applications of stem cells, current 
scientific expectations of stem cell research, and whether the candidates are for or against stem cell 
research, which is not always consistent with the Democratic or Republican Party’s general stances. 
For the past decade, the magnitude of the potential of stem cell research has been a focus of interest 
for science and a large source of debate for the general public. This issue was first focused on in the late 
1990s when human ESCs were cultured for the first time. It was found that these cells possess the 
unique property of being able to self-renew and differentiate to become any other type of cell in the 
human body. 
Although this immediately opened up the possibility of treating certain medical conditions that are due 
to the loss of a specific cell-type by replacing them with those created from ESCs, the subject became a 
political issue of ethics versus science. Opponents of ESC research argue that when embryos are 
destroyed, a necessity for acquiring ESCs, a human being is killed. 
Opponents also argue that other sources of cells are available. Recently, there have been breakthroughs 
that allow pluripotent stem cells to be induced using adult cells, which do not require the destruction of 
embryos. On the other side of the argument, problems that cannot be overlooked exist with using 
induced pluripotent stem cells as alternatives; therefore ESCs are still considered the gold standard, 
offering important advantages as far as medical applications are concerned. One goal of this report is to 
help people who do not closely follow the scientific research literature understand the basics of stem 
cells, including the different types, the medical applications, and the possible alternatives. 
Since this issue became a political topic, funding for ESC research has been limited by the federal 
government in the U.S. While some proposals for stem cell research funding have been approved by 
Congress, others have been voted against or set aside before a decision could be made. Since this issue 
is so prevalent in politics and the presidential election has put some of its focus on support or opposition 
by the candidates and their running mates, one purpose of this report is to make the general public 
aware of the candidates’ stances on the issue. Observations will be made based upon not only what 
they have said and what they cite as reasons, but also how they have voted in the Senate to determine 
consistency between their positions and their voting records. This information was also used to predict 
the future of stem cell legislation, once the outcome of the presidential election is decided. 
Stem cell research has been reported on frequently by the popular press. Unfortunately, because of 
widespread circulation, there is more exposure for most people to mainstream media such as 
newspapers rather than reports by scientists doing the actual research.4 Another purpose of this report 
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is to make voters aware of the true present potential of stem cell research, pointing out the common 
dramatizations and presumptuous exaggerations made by the media. 
The primary outcome of this report is the summary of results. The results are arranged in a user-friendly 
pamphlet (Appendix 1), which simplifies the complicated scientific, media, and political issues of stem 
cells. The pamphlet was distributed throughout the WPI campus a week before voting day (November 4, 
2008) at spots designated for usual popular press distribution such as newspapers. 
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Methodology 
 
To accomplish the goals of this project, slightly different methodologies were employed for each 
section. The different sections where methodology varied were the compiling of scientific knowledge, 
politically-related information, and media and journals. 
The scientific knowledge was the first area of the project that we gathered sources for. We used 
textbooks to gather general knowledge of stem cells. The information from textbooks was very 
particular in the sense that it explained how stem cells can be applied, but it gave little to no timeline 
regarding discovery of applications. To explain stem cells in slightly more detail, we found several 
medical journals on the subject. We used original articles from when ESCs were first discovered and 
documented. Newer journals were used only from the times adult stem cells were being discovered 
and/or investigated. 
Next we focused on gathering information for the political section. Most of our data came from the 
Government Press Office. From here we gathered the 2004 and 2008 party platforms, voting records, 
and bills affecting stem cell research and its funding. This information, combined with any press releases 
and speeches made by the candidates, allowed us to fully explain and support the candidates’ apparent 
stances on the stem cell issue. 
The final major segment of the report was the compilation and analysis of the media’s reports to assess 
the accuracy of the information and whether or not it was appropriately conveyed when compared to 
the scientific journals upon which the articles were based. When searching for newspaper articles, the 
ones chosen for this project were the local ones. Several from the Boston Globe and New York Times 
were selected because of their wide distribution in Massachusetts and at WPI. A second criterion for the 
media articles was that they were spanned the past 10 years. Older articles were compared to more 
recent reports to allow analysis of the media’s portrayal of stem cell research over the years. 
These three major sections of the project were for the most part developed independently of each other 
since they each serve to accomplish a different objective. Compiling all three allows the one overall goal 
of the project to be accomplished. That one main goal is to allow voters to make informed judgments 
about the stem cell issue when they gain knowledge about the scientific aspect of ESC research, the 
political agendas and stances of each party and candidate, and can properly interpret the media’s 
reports on updates about the issue. 
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Figure 1: Cell Life Cycle. 
The outer ring: Orange is interphase 
and the yellow is Mitosis. The inner 
ring: G1 (Blue) is the first growth 
phase, S (Red) is the DNA synthesis 
phase, and G2 (Green) is preparation 
of mitosis. G0 phase (Turquoise) is the 
phase in which most mammalian cells 
reside.3 
Scientific Background 
 
Embryonic Stem Cells (ESCs) are a special class of cells derived from 5-day-old blastocysts with age zero 
being the fertilization of the egg by the sperm.5
Self-renewal, in the context of cell biology, describes the ability of cells to replenish the population of 
cells lost in an organism. Stem cells, like most single-celled organisms, go through a process known as 
mitosis to produce more cells. The parent cell – the original cell – gives rise to two identical daughter 
cells, the products of mitosis. (Figure 1) The life-cycle of a cell is referred to as the cell-cycle and is 
comprised of distinct events in a determined order. The events of the cell cycle, which include both 
interphase and mitosis, are very strictly controlled through internal 
chemical signals. Most single-celled organisms and stem cells use 
this process to produce copies of themselves.
 These cells belong to a larger class of cells known as 
stem cells. Stem cells possess some very unique characteristics not found in other mammalian tissue 
cells: they have the ability to constantly self-renew. Most cells found in mammals do not divide, unless 
signaled by external chemical cues, and are lost through natural processes such as shedding of skin cells. 
These cells are replaced by either stem cells or cells derived from stem cells. 
6 Unlike most single-
celled organisms, most cells in mammals, such as heart cells and skin 
cells, do not follow the circular pathway shown in Figure 1. These 
cells during the G1 phase leave the circular pathway and enter the G0 
phase. During this phase, the cells will go through all normal 
metabolic processes, except those necessary to prepare for mitosis. 
These cells will exit this quiescent phase if they are signaled by 
external chemical signals known as growth factors.6 Stem cells, 
unlike all other cells in mammals, do not enter the G0 phase and 
proceed with the cell cycle. The self-renewing stem cells, besides 
replenishing the stem-cell supply, constantly compensate for loss of 
other cell types and growth of the organism.6 A great example of this 
is epithelial cells such as skin cells. Skin cells are constantly replaced 
by descendants of stem cells. This conversion of stem cells, which 
have the ability to self-renew, to specific types of cells such as skin 
cells, is known as differentiation. 
The process of differentiation allows stem cells to convert into all the other cell types found in the body. 
The transformation of stem cells to tissue-specific cells proceeds through intermediate steps in the form 
of different cell types, each becoming closer in structure and function to the final cell-type (Figure 2). A 
feature to notice of the expanding table is the lack of self-renewal except for the hematopoietic stem 
cell. Hematopoietic stem cells are one of the types of multipotent stem cells found in the human body. 
They give rise to all the different components of blood. The hematopoietic stem cell after mitosis 
produces a hematopoietic stem cell and either a myeloid or lymphoid cell. The myeloid and the 
lymphoid cells do not produce copies of themselves as they proceed through the cell cycle. Instead, they  
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Figure 2: Hematopoietic Stem Cell Differentiation1 
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give rise to different cell types. This cascade continues until terminal cell differentiation is reached. In 
Figure 2, these would be erythrocytes, macrophages, platelets, granulocytes and lymphocytes.6 Another 
unique feature of the cascade is the increase in number of cells after each subsequent division. All the 
mitotic divisions, except for the mitotic division of hematopoietic stem cells, cause an increase in cell 
number. This exponential increase in the cell number has a very significant consequence. It allows one 
stem cell to give rise to many tissue cells such as red blood or platelets, and theoretically to an entire 
organism, if the stem cell is capable of dividing into all the different cell types necessary to produce an 
organism. 
Stem cells with the ability to divide into any tissue in an organism are classified as pluripotent stem cells 
(Figure 3). These stem cells, during the development of an embryo, give rise to all three germ layers: 
endoderm, ectoderm, and mesoderm. The germ layers are layers of cells found in the growing embryo 
and have the ability to give rise to different organ tissues (Figure 3). These cells are considered to be 
stem cells, because they can give rise to different types of tissue cells; however, a particular germ-layer 
cell can only give rise to limited types of organ tissues. Pluripotent stem cells, during normal embryo 
development, arise from totipotent stem cells, which arise directly from the fertilization of an egg by a 
sperm. After the fertilization 
event the zygote or fertilized 
egg divides to give rise to a 
blastocyst. It is possible, 
through modern techniques 
pioneered by James Thomson, 
to extract ESCs from a 
blastocyst.7 In the paper 
published by Thomson in 
1998, embryos from in-vitro 
fertilization clinics were used 
to derive the cells. These 
embryos were obtained 
through donations from 
individuals with informed 
consent with the oversight of 
the institutional review board. 
In the paper, Thomson 
reported the derivation and culture of stable cell lines with characteristics very similar to stem cells from 
other primates. The derived stem cells also showed a normal karyotype.7 A karyotype is a visual 
depiction of the chromosome structure of a cell achieved through the use of dyes. A karyotype analysis 
is important, to determine whether the expected number of chromosomes, 46 for human beings, is 
present within the cell. The karyotype also shows any abnormalities, such as missing pieces, in each of 
the chromosomes. Cells with abnormal karyotypes, especially aneuploid cells (cells with extra or missing 
chromosomes), can give rise to syndromes such as Down syndrome. 
Figure 3: Cell Differentiation Hierarchy 
The cells in similar color boxes can be considered to be on the same level in the 
hierarchy. The orange boxes are just a representative of the many different cell 
types which develop from the germ layers. 
11 
 
The derived stem cell line also showed high telomerase activity. Telomerases are enzymes involved with 
replacing the DNA lost from the ends of the chromosomes (known as telomeres) during the S-phase of 
cell cycle. High telomerase activity within a cell implies the ability to go through mitosis, because 
telomeres are necessary for cell division. During each cycle of DNA replication, which is performed 
during the S phase, cells lose pieces of telomeres unless they are replaced. The loss of telomeres can 
cause cell death or cell senescence. Senescence of cells refers to the loss of the ability to divide through 
mitosis, and cell senescence prevents cells from giving rise to other cells.6 During the process of DNA 
replication, the replication machinery needs a starting point. These starting points, also known as 
primers, are composed of RNA. The primers attach to the DNA and the replication machinery replicates 
DNA in one direction. The replication machinery can replicate in only one direction; the chemical 
reasoning for this is beyond the scope of this paper. Due to the directional constraint on the replication, 
it is not possible for the replication machinery to replace the RNA primers with DNA and results in the 
loss of some DNA with the primer, resulting in shortening of the telomeres. This replenishing of the 
telomeres by telomerase allows cells to divide indefinitely; therefore, a high-level of telomerase activity 
indicates ability to divide indefinitely, a characteristic of stem cells.6
Thomsen’s successful development of ESCs from blastocysts and the ability of ESCs to develop into many 
different tissues in the body provide many different potential therapeutic applications for ESCs. 
Although ESCs can theoretically provide treatments for different pathologies, the source of ESCs has 
caused controversy. Thomsen and his team used blastocysts donated from In-Vitro Fertilization (IVF) 
clinics to derive the cells. In-vitro fertilization, a 
medical procedure, involves the fertilization of an 
egg from the mother by the sperm from the 
father outside of the human body, essentially “in 
a test tube.” Due to the complex nature of the 
process, many eggs are fertilized simultaneously 
to assure a few healthy and viable zygotes. The 
zygotes are allowed to develop for approximately 
5 days and gauged for their health.
 
5 At this point, 
the cell mass develops into two different cell 
layers. The inner layer develops into the embryo. 
The outer cell layer is responsible for giving rise 
to all the structures necessary for supporting the 
embryo, later called a fetus, through the 
pregnancy (Figure 4). At this stage of 
development no prominent features such as 
germ layer cells or rudimentary organs are 
present, and the blastocyst must successfully attach to the uterus to continue developing. The 
blastocyst, from a scientific point of view, is a ball of cells with two distinct layers.8 Depending on the 
health of the blastocysts and the number of children the couple would like, a fixed number of 
blastocysts are placed in the womb of the mother. The remaining, which are either deemed as extra or 
not healthy enough for transplantation into the womb, are either discarded as medical waste or frozen 
Figure 4: Schematic drawing of blastocyst development 
The fertilized egg develops into a blastocyst (yellow ball) 
from which all human cells are created. The inner cell mass 
was used by Thomsen to create human ESCs.2 
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for later use.5
Ethical Concerns 
 When blastocysts are used for creating ESC lines by extracting cells from the inner cell 
mass, they are destroyed in the process.  
 
For many critics, destruction of a blastocyst is the destruction of innocent human life. The use of 
blastocysts from IVF clinics also gives rise to issues such as human cloning and embryo farming, which 
are considered unethical by both the proponents and the critics of ESC research. Embryo farming refers 
to a practice of intentionally fertilizing eggs to extract cells or organs from the fetus with no intention of 
bringing the embryos to term. The critics of ESC research also bring about the ethical arguments 
regarding possible inception and growth of embryos for the sole purpose of providing ESCs for 
therapeutic uses, because it would translate to the destruction of one human life for the benefit of 
another. The critics also argue for the use of alternatives. These alternatives are adult cells which have 
been shown to have similar properties as embryonic stem cells. 
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 Non-Embryonic Stem Cell Sources 
 
IPS Cells 
 
One of the obstacles facing therapeutic research with ESCs is the low number of cell lines and the lack of 
federal funding for the creation or use of any new stem cell lines. The lack of funding and scarcity of cell 
lines has increased research in possible alternatives to ESCs. The research in this field has boomed lately 
due to the discovery of procedures allowing the reversal of the differentiation process, essentially 
allowing differentiated, tissue-specific cells to enter an embryonic stem cell-like state. These cells are 
referred to as induced pluripotent stem cells. (iPS cells) 
The induction of an ESC-like state in differentiated cells requires a significant disruption in the normal 
cell cycle pathway in the form of introduction of four genes, Oct3/4, Sox-2, c-Myc, and Klf-4, through the 
use of a retro-virus.9 According to an article, describing the conversion of adult human cells into 
pluripotent stem cells, published in the journal Cell in 2007, Oct3/4 and Sox-2 are transcription factors 
and increase the expression of genes that give cells stem-cell like characteristics, whereas the Klf-4 
allows the Oct3/4 and Sox-2 to interact with DNA.10 Transcription factors are proteins that bind to DNA 
and regulate gene expression in a cell. Gene expression is extremely important, because changes in gene 
expression have consequences on all the different processes occurring in a cell. The difference in these 
processes provides for the diversity amongst all the cells found within the human body. The addition of 
the four genes affects the morphological characteristics of the cells – the physical structure of the cell –, 
especially the expression of certain genes and endows upon the cell the ability to self-renew. The gain of 
the self-renewal ability is one of the unique characteristics of stem cells. These cells were also shown to 
differentiate into neural and cardiac cells.10  The transcriptions factors used, especially c-Myc, are known 
to induce tumors in normal mammalian cells. Tumor generation was observed in approximately 20 
percent of the cells, a risk too high for therapeutic use.9 
 
It is important to note that generation of a 
specific type of tumor (known as a teratoma) in mice is one of the criteria for classification as stem cells. 
Therefore, the potential for tumorigenesis is not necessarily an undesirable feature. It is not known 
whether the cells continue to produce tumors after they have differentiated into a particular cell-type. 
Hematopoietic Stem Cells 
 
Aside from induced pluripotent cells, there are other alternatives to ESCs. One is the use of multipotent 
cells available in the patient’s body. This includes hematopoietic stem cells found in the bone marrow of 
patients. There are key advantages to using a patient’s own cells, including the elimination of tissue 
rejection. The varying amount of different multipotent cell populations available in the body can limit 
their therapeutic use, especially in areas where very few multipotent cells support a large population of 
14 
 
differentiated cells. The most promising results are seen with hematopoietic cells partly due to the 
extensive knowledge of the pathologies concerning these cells and their presence all around the body. 
One study showed the use of hematopoietic stem cells for retinal rod regeneration in mice. The data 
published in the same paper also showed the positive effects to the nerves near the rod.11
 
 
Multipotent Adult Progenitor Cells 
 
An alternative similar to hematopoietic stem cells that showed some positive results, at least in mice, is 
the use of multipotent adult progenitor cells. An article published in the journal Nature in 2002 showed 
differentiation of mesenchymal cells into representatives of all three germ layers: mesoderm, 
endoderm, and ectoderm. Mesenchymal cells are derived from the mesoderm and give rise to various 
different kinds of connective tissue within the body. These cells, when injected into blastocysts, 
contributed to most of the different somatic cell types. Somatic cells are cells that are present in an 
organism but do not give rise to a sperm or an egg. This data shows the ability of these cells to 
differentiate into all different types of cells. The paper also reports the expression of mouse ESC markers 
on these cells, indicating that these cells may behave like mouse ESCs in response to external messages 
from other cells in the body. These cells were also shown to lack teratoma formation in mice. The lack of 
teratoma formation combined with other data such as the presence of certain markers and 
differentiation observation show possible therapeutic potential. There are key advantages to using cells 
found within an individual. One of the greatest impediments in organ or cell therapy is the rejection of 
organs or cells.12 It is possible to avoid rejection of the therapy by using the patient’s own cells, because 
the body will recognize them as part of it rather than an external entity. These cells, according to the 
Nature 2002 article, can be used as model for therapeutics for diseases such as muscular dystrophy.12 
Although hematopoietic stem cells and multipotent adult progenitor stem cells do show potential as an 
alternative to ESCs in certain areas, there are still conditions for which ESC therapeutics are the only 
cellular therapies possible. Many of the conditions dealing with the nervous system such as Alzheimer’s 
and Parkinson’s disease have only shown successful pre-clinical (mouse studies) results in studies with 
ESCs. 
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Stem Cells in National Legislation 
Ethical Dilemma 
 
 Currently embryonic stem cells are derived from unused blastocysts acquired from IVF clinics. The 
source of the embryonic stem cells causes an ethical dilemna. This ethical dilemna is usually a deciding 
factor from many who wish to take a stance on whether to support or oppose ESC research. ESC 
research in the past has been a very heavily debated issue (Figure 5), and it brings in arguments from 
the political and religious realms. Like many national issues, the two major political parties have differing 
views on the subject of ESC research. The Democratic Party supports expansion of stem cell research, 
whereas the majority of the Republican Party does not support the expansion of ESC research. (Table 1) 
Before proceeding with the discussion of the difference in arguments between the supporters and the 
critics, it is very important to delineate between different types of stem cell research projects and 
initiatives. It is very common to group all research pertaining to different kinds of stem cells under a 
generic umbrella term; however there are significant differences between the groups. This delineation, 
mainly between adult stem cell research and ESC research, is important to understand the political and 
ethical arguments on the subject. The definitions vary depending on the use of the cells and the source 
of the cells. For the context of this report, ESCs are cells that use the blastocyst as the source of the cells. 
As mentioned in the background section, these cells are pluripotent and give rise to all three germ 
layers. Multipotent cells (such as hematopoietic stem cells) show properties of stem cells but do not give 
rise to all different types of tissues in the body. Many critics of ESCs are proponents of adult stem cell 
research. This includes research to find therapeutic uses and alternative sources, like those mentioned 
earlier, to ESCs. Many members of the Republican Party, who do not support funding of new ESC lines, 
support the funding of research aimed towards finding alternative sources of stem cells. 
The critics of ESC research – both Democrats and Republicans – have one common opposition: the 
destruction of human life in the process of creating stem cell lines. Many critics of ESC research consider 
the fertilization event – the meeting of the sperm and the egg – as the beginning of human life. 
According to the critics, the blastocyst is considered to be a human being rather than just a body of cells, 
and the destruction of the blastocysts is the destruction of innocent human life.13 This argument, at its 
root, is very similar to the controversy regarding abortion. This does not imply that there is any 
Figure 5: Key Statements in the Embryonic Stem Cell Debate. 
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correlation between the stance of an individual on the issues of abortion and embryonic stem cell 
research. However, the supporters of ESC research do not consider the fertilization event to be the 
beginning of human life. According to the supporters, the destruction of blastocysts used for creating 
the ESCs are not human fetuses, and the destruction of blastocysts is considered to be different from 
the destruction of a human being. Although the supporters of ESC research do not consider the 
destruction of a blastocyst equivalent to the destruction of innocent human life, many supporters still 
do not support the creation of blastocyst for the sole purpose of its destruction to produce ESC lines. 
The controversy may disappear, if it was possible to scientifically show the loss of one cell from the 
blastocyst is not detrimental to the blastocyst. Although the experiments to prove this would be 
unethical, some scientists have observed under control settings the growth of blastocysts used to derive 
embryonic stem cells. These blastocysts were stopped very early in the growth process.14
 
 
Stem Cell Legislation 
 
Four pieces of legislation were analyzed to study the views of Senator Barack Obama and Senator John 
McCain. The voting record on the issue is short not due to a lack of bills and initiatives; rather many 
relevant bills have been introduced and have been given to committees. Many of these bills have been 
in committee for 5-6 years. These bills may never be discussed or are being superseded by more 
pressing issues such as economic conditions. The four pieces of legislation, which were voted upon by 
the Senate, included two bills which were very similar to each other: Senate 5 (S 5; Appendix 4) and 
House of Representatives 810 (HR 810; Appendix 2). Both of these bills were Stem Research 
Enhancement Acts with the goal of allowing further creation of stem cell lines with ethical clauses. These 
bills were intended to remove the ban introduced by President Bush at the start of his first term on the 
funding of newly created ESC lines. The bills provided necessary checks to prevent unethical use of 
blastocysts such as producing an annual report for Congress regarding all of the activities performed 
through federal funding. 
S 5, the Stem Cell Research Enhancement Act of 2007, also supported the creation of funding for 
alternative stem cells sources. These alternative sources, as discussed above, do not require the 
destruction of embryos, while providing cells with all the necessary characteristics for therapeutic use. 
Another bill supporting alternative pluripotent stem cell derivation is Senate 2754. Senate 2754, also 
known as the Alternative Pluripotent Stem Cell Therapies Enhancement Act, provided for more funding 
into ESC alternatives. This act also promoted a priority system for near-completion therapeutics to 
accelerate this research rather than new and exploratory research. 
The last relevant piece of legislation also provides the only voting disparity between the two Senators. 
Senate 30, also known as the HOPE Act, has many of the same clauses as the previously discussed pieces 
of legislations with one exception: it specifically requires that scientists not alter any timing mechanism 
of blastocysts to derive human ESCs. This prevents the derivation of ESCs from blastocysts. At the roll-
call vote for this particular legislation, Senator Barack Obama voted against the bill, whereas Senator 
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John McCain voted for the bill. Both candidates voted along party lines; however Senator McCain had 
previously voted against his party on the Stem Cell Research Enhancement Acts (Table 1). 
 
Impact in the Legislation 
 
Table 1: Senate Votes on Key Stem Cell Bills 
 
The ethical dilemmas have shaped the legislation, and the effect is seen very clearly in the bills passed 
by the Senate and the House regarding ESC research. The bills pertinent to this issue have one common 
thread: the ethical clauses put on the sources of the embryos. Both The Stem Cell Research 
Enhancement Act of 2005 (HR 810; Appendix 2) and the Stem Cell Research Enhancement Act of 2007 (S 
5; Appendix 4) address the issue of federal funding for the establishment of new ESC lines. The bills 
consisted of ethical clauses limiting the source of ESCs and the procurement of these sources. The most 
common source of ESCs cited in the congressional bills is blastocysts from in-vitro fertilization clinics. 
 Obama  McCain  Biden  Republican 
Party  
Democratic 
Party  
Passage of H.R. 810 
Stem Cell Research Enhancement 
Act of 2005 (Appendix 2)1 
Yea  Yea  Yea  Nay  Yea  
Passage of S. 2754 
Alternative Pluripotent Stem Cell 
Therapies Enhancement Act 
(Appendix 3)2 
Yea  Yea  Yea  Yea  Yea  
Passage of S. 5 
Stem Cell Research Enhancement 
Act of 2007 (Appendix 4)3 
Yea  Yea  Yea  Nay  Yea 
Passage of S. 30 
Hope Offered through the 
Principled and Ethical Stem Cell 
Research Act 
(HOPE Act) (Appendix 5)4 
Nay  Yea  Yea  Yea  Nay 
Notes: 
1 HR 810 provides funding for embryonic stem cell research. (See Appendix 2 for full text) 
2 S 2754 supports alternatives to embryonic stem cell research and supports research of treatments. 
(See Appendix 3 for full text) 
3 S 5 provides funding for embryonic stem cell research as well as alternatives. (See Appendix 5 for full 
text) 
4 S 30 would put more funding into alternatives to embryonic stem cell research, but saying yea does not 
necessarily mean the candidate opposes embryonic stem cell research. (See Appendix 6 for full text) 
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The ethical clauses found within HR 810 and S 5 consisted of clauses to prevent intentional creation of 
blastocysts for the purpose of ESC line development or the commercialization of the blastocyst donation 
process. Each bill put forth explicit requirements regarding the source of the blastocyst. For federal 
funding of the research, the bills require the blastocyst to be created for fertility treatment and to be in 
excess of the need of the fertility treatment. The bills also prohibit any monetary compensation for the 
individuals who decide to donate the blastocysts to prevent all and any motivations for the intentional 
productions of the blastocysts. The bill further requires only those blastocysts that would never be 
placed in a woman’s womb be used for the creation of embryonic stem cell lines. This clause is 
necessary due to the Snowflake Program, which gives the individuals who donated the egg and sperm 
the option of donating the blastocysts to other individuals. The Snowflake Program is not a government 
supported program rather it is a program which is supported through a private organization: Nightlight 
Christian Adoption. The Snowflake Program, like any other adoption agency, provides matching service 
for biological parents and adopting parents; however unlike other adoptions, an embryo adoption is 
given birth by the adopting mother rather than the biological mother: egg-donor.15
 
 
Presidential Candidate Stance 
 
The two stem cell research enhancement acts discussed 
above were approved by the Senate and the House. The 
votes in the Senate on the two bills show an interesting trend 
between the two candidates. Senator McCain, the 
Republican Presidential candidate, Senator Obama, the 
Democratic Presidential Candidate, and Senator Biden, the 
Democratic Vice-Presidential Candidate, all voted “yea” on 
this bill (Table 1; Figure 6). The votes of Senator Obama and 
Senator Biden can be expected, because they are in 
agreement with the Democratic Party line of 
supporting ESC (Cartoon 1).16,17,18 Senator McCain’s 
vote for the passage of both HR 810 and S 5 are not in 
accordance with the Republican Party line. The voting 
records indicate a similarity in opinion between the 
two Presidential candidates and the Vice-Presidential 
candidate. This similarity is further extended in the 
statements made by Senator McCain and Senator 
Obama on the issue of ESC research, in particular the 
funding of new cell-line creation. Both Senators 
McCain and Obama addressed the importance of 
creating new cell lines in a regulated and ethical 
manner. Both addressed the issue of “embryo-
Figure 6: Graphic depicting the views of the two 
Presidential Candidates on the issue of ESC 
research. 
Cartoon 1: This political cartoon mocks the Democratic 
Party for their united support for stem cell research. 
Used with the permission of Grimmy, Inc. and the 
Cartoonist Group.  All rights reserved. 
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harvesting.” Both senators, in their floor statements, implored the Senate to approve the bill due to the 
possible therapeutic uses of stem cells. They both consider ESC research to be a necessity and believe 
the ethical concerns can be addressed through proper regulation and control of the research. Both 
Senators also acknowledge the need for legislation due to the highly unregulated research occurring in 
the private industry.19,20
 
 
Political Party Stance 
 
Unlike the shared opinions of the Presidential candidates, Senator Obama and Senator McCain, there is 
a clear difference in the stance of the two political parties on the issue. The Democratic Party, as seen in 
Table 1, supports the expansion of embryonic stem cell research and the lifting of the current bans on 
federal funding of newly created stem cell lines.17 The current push for lifting the bans is especially 
evident in the voting record of Senator Obama, who rejected the passage of Senate 30. Senate 30 
proposes allocation of funding for alternative sources, which Senator Obama supports, but the bill also 
puts stringent restriction on the funding available to new stem cell lines. These restrictions, in most 
cases, render the creation of new federally-funded embryonic stem cell lines impossible. 
The Republican Party, unlike the Democratic Party, does not support the expansion of embryonic stem 
cell research. The arguments used by the Republican Party are similar to the arguments used by the 
critics of embryonic stem cell research: the destruction of human embryos. The Republican Party, as 
seen in Table 1, does support the funding of alternatives and many members of the Republican Party are 
proponents of non-embryonic stem cell research. The views of the Republican Party, at least in the party 
platforms, have changed from the 2004 Presidential Election to the 2008 Presidential Election. In the 
2004 Party Platform, the Republican Party provided a very thorough explanation defending the party 
stance on the issue.21 In the 2008 Party Platform, the issue of embryonic stem cell research is mentioned 
and the party stance is stated, but unlike the 2004 stance, the 2008 stance is written in a less strongly-
worded manner.22 
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Future of Stem Cells in Legislation 
 
The election of the Democratic Party presidential 
candidate, Barack Obama, will change the course of 
stem cell legislation. President Bush, the incumbent 
President, severely opposed ESC research requiring the 
further destruction of human embryos and creation of 
new ESCs (Cartoon 2). President Bush vetoed both HR 
810 and S 5; HR 810 (Appendix 6) was the first 
presidential veto used by President Bush during his 8-
year presidency. On the other hand, President-Elect 
Obama’s voting record in the Senate shows a clear and 
strong support for the advancement of all aspects of 
ESCs, including the development of new ESC lines and 
new alternative ESC sources. While Barack Obama’s 
current Senate voting record would indicate he would 
sign bills advancing ESC into law, Barack Obama is a strong advocate for ethical research. Barack Obama 
cites the lack of ethical limitations in legislation of other foreign nations and the lack of ethical 
limitations in the private sector as a reason for the further expansion of government-supported ESC 
research in the US.19 ESC bills during the Obama Presidency must contain clauses establishing ethical 
guidelines for research. These may include clauses establishing no intentional creation of embryos for 
cell line derivation and establishing conditions preventing any financial gain from occurring for the 
production of these embryos. Both of these clauses along with other more restrictive clauses were 
found in both S 5 and HR 810. The control on financial gain from the production of embryos is necessary 
to pursue ethical and humane research, but a constant supply of embryos would be necessary to 
provide new cell lines as ESC lines were established from cells derived from blastocysts.7 The lack of 
financial gain from the production of a steady supply may deter industries within the private sector from 
providing a supply. The derivation of new stem cell lines from blastocysts poses another issue: storage 
of blastocysts. Blastocysts need to be stored in liquid nitrogen or cold gaseous nitrogen for long term 
storage, which is expensive.23 Currently, due to the ban on federal funding for the creation of new stem 
cell lines, blastocysts are only stored for IVF patients, and the cost of this is incurred by the donors of the 
egg and the sperm.5 With the possible use of blastocysts to create ESC lines, possible legislation would 
need to include clauses establishing procedure for transfer of ownership and whether the parents are 
provided by the research organization with the cost incurred by the parents in the storage of embryos A 
clause establishing the burden of payment during any transfer of ownership, if such term is appropriate, 
would also violate the current clause prohibiting any money transfer for the procurement of blastocysts 
to prevent embryo farming. Due to the complex economic issues posed, any legislation would need to 
establish clear boundaries regarding any costs incurred during the development of ESC lines, as well as 
who is to incur the cost. 
Cartoon 2: A political cartoon mocking the Bush 
embryonic stem cell policies.  
Used with the permission of Grimmy, Inc. and the 
Cartoonist Group.  All rights reserved. 
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Although a Democratic Congress and a Democratic President would further the progress of embryonic 
stem cell research legislation, the issue of stem cells is many times overshadowed by other issues, 
especially economic issues. During the Bush Presidency, only two stem-cell related bills introduced in 
either the Senate or the House reached the President’s desk: S 5 and HR 810. This number can be 
contrasted with the approximately 2000 bills which have been enrolled by the Senate and the House 
and sent to the President’s desk during the Bush Presidency. Aside from S 5 and HR 810 other stem cell 
bills have been introduced into the Senate and the House, but these bills have yet to leave committees 
or be passed by both the Senate and House, and many are being postponed for other issues.i This may 
change once President Obama takes office. According to his Chief of Staff, Rahm Emanuel, embryonic 
stem cell legislation change is on the Obama priority list, second only to child health-care.24
                                                          
i A search of the legislative database THOMAS at Library of Congress with Keywords “Embryonic Stem Cell 
Research” yields many different bills and most these bills are on committee calendars. 
 This may be 
a sign for a prosperous and active future for embryonic stem cell research legislation.  
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Media and Journals 
Late 1990s 
 
Originally, ESCs were covered by the media because of their novelty. The focus of new articles in the late 
1990s was on stem cells in general, because lay audiences were not yet familiar with them to any 
extent. On the other hand, scientists were also not yet very familiar with them, either, and as a result, 
were not sure how easily they could be manipulated and used for clinical treatments. Articles reporting 
on early stem cell research sometimes made claims that seemed too good to be true and in most cases 
were, but this was not always the case since there were no high expectations of stem cells like there are 
today. 
One such article, “Engineering body parts from scratch,” appeared in the November 11, 1999 issue of 
The Boston Globe. The article explores the potential of constructing parts of the body using stem cells in 
order to renew a person’s soft tissues, cartilage, ligaments, and bone. It reports that these replacements 
are “not far off, scientists say.”25 
The article presents these predictions, but does not report any actual advances regarding the research 
of stem cells. The only information it has about stem cell research that has been completed is that 
scientists isolated them for the first time less than a year before the article was published. It never 
suggests any reasons why manipulating stem cells should be a simple scientific feat, nor does it provide 
any research results that scientists are actually near completing construction of “body parts from 
scratch” other than scientists saying they are.25 
Another article, written and published around the same time, is less misleading when discussing the 
medical advances using stem cells, demonstrating an inconsistency in overall media reporting regarding 
stem cells. The article, “Boy cured using experimental blood transfusion” was released by the Associated 
Press on December 13, 1999. It reports on an operation which had been performed a year prior. A 13-
year-old boy had umbilical cord blood stem cells transplanted to replace his bone marrow, and he was 
declared cured one year later. At the end of the article, it very plainly states that the success rate of such 
an operation is estimated to be 50-50 so it does not mislead readers into thinking the operation is 
flawless.26 
Although no medical journal articles were referenced or cited, one had been published in 1998 reporting 
results of the first 50 patients undergoing the transplantation in Belgium. It more than validates the 
newspaper article, actually reporting survival rates from the transplantations at over 80%.27 
From these two articles, no conclusion can be made about the consistency of exaggerated claims when 
stem cells were first reported on. It should be noted that neither article cites any scientific journal 
article, which makes it difficult for the reader to determine the validity of claims. 
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Early 2000s 
 
As years passed, the media focused less on explaining basic principles than they did when stem cells 
were first discovered. In the early 2000s, ethical issues were more frequently the focus of news articles. 
One article that demonstrates this is “’Politically Correct’ Stem Cell is Licensed to Biotech Concern,” even 
mentioning the political agenda in the title.28 The article does not go into much detail about the actual 
science of stem cells; instead, it focuses on the companies that are researching them and which stem 
cells they are researching specifically. 
The type of stem cell, whether embryonic or adult, is the focus of the political controversy, as it still is 
today. The article only focuses on the politics and business aspects of the situation because the scientific 
aspects in this case are controversial in the sense that no real evidence has been published that the 
adult stem cells they use are actually as versatile as ESCs. 
Published around the same time as the newspaper article were three science journal articles, co-
authored by Dr. Catherine M. Verfaillie, who was credited with the discovery of multipotent adult 
progenitor cells in the newspaper article. In each of these journal articles however, it clearly states that 
the cells discovered are multipotent, rather than the more versatile pluripotent ESCs.12, 29, 30 The 
newspaper mentions that they are multipotent, but at the same time claims that they are no less 
capable of differentiating as totipotent ESCs are.28 
There is one medical prediction made in the article, and it is not until the very end. After only discussing 
rights to the research, the article ends by making the prediction that the company conducting the 
research, Athersys, hopes “to start the first clinical trial using the cells, probably to treat a rare genetic 
disorder, in two years.”28 Based only on this information, it is impossible for the reader to gather any 
further information about the type of genetic disorder, whether or not the scientists think it will be 
successful, whether or not these new types of cells will actually live up to expectations, or whether or 
not any genetic disorder can reasonably be expected to be cured in a matter of a few years. 
Other media articles around this time start delving into the science behind stem cells more than in the 
past. One article published in the New York Times, “Progress Is Reported on Parkinson’s Disease,” 
specifically mentions chemicals and genes used in the experiments. It describes experiments in which 
Parkinson’s-like symptoms were induced by chemicals in mice so that they could be cured by ESCs.31 
The results are presented, but can be misleading to the reader. The article is set up so that the more 
promising aspects of the research are mentioned first, and the scientists that are quoted are much more 
optimistic at first. Even the title sounds promising, as well as the pull-quote in the middle of the page. 
Near the end of the article however, the scientists still say that “a lot of work is needed to straighten out 
the kinks.” This does not stop them from predicting clinical trials to begin in about four years.31
The medical journal article that the newspaper article is based on provides much of the same hope for 
potential treatment of Parkinson’s disease, but it also points out the drawbacks which the newspaper 
failed to mention. This treatment may result in the formation of tumors if the cells continue to divide in 
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vivo. Also, there is potential for schizophrenia, which is related to the dopamine and serotonin neurons. 
These potential flaws alone require much more long-term research.32
 
 
Although the newspaper articles from the early 2000s are more scientifically involved, based on 
scientific journal publications, and even point out some of the pessimisms that come with stem cell 
research, they tend to exaggerate the results or present them in a misleading way. 
Late 2000s 
 
In the past, the political implications of supporting or opposing ESC research have been apparent, but 
were not as significant as recently. Even around election times, it was a matter of ethics without 
emphasis on alternatives. With the recent breakthrough of being able to induce pluripotent cells from 
adult stem cells rather than using cells from human embryos, as well as the upcoming election, the 
political debate has been reinvigorated. 
There have been several articles in the past year that have reported on this new form of stem cells, and 
they all focus on discussing the political implications of the achievement. One article, published in The 
Boston Globe in November 2007, describes the new cells and how they are pluripotent just like ESCs. It 
does not make it through the first paragraph without introducing the theory of ending the stem cell 
controversy “avoiding the controversial creation and destruction of embryos.”33 
One hailed aspect of the new embryonic-like cells is the fact that they are not exempt from receiving 
federal funding. There is a clear difference in opinion between scientists and religious activists shown. 
The scientists believe it is good that funding may be made available to research this alternative to ESCs, 
but they make it clear that “this is early stage research, and we should not abandon other areas of stem 
cell research.” On the other hand, religious activists are fully ready to completely support the move from 
embryonic cells to induced pluripotent cells.33 
When new stem cell discoveries are made, such as the original stem cell research or induced pluripotent 
stem cells, the media tends to pay more attention to and have a lot of hope about these endeavors. 
Once more research is done and obstacles are discovered, articles in the last year or so tend to be more 
based upon the political debate in the sense that they present facts from both sides of supporting and 
opposing ESCs and/or moving to induced pluripotent stem cell research only. 
An article published several months after the initial repot of induced pluripotent stem cells being 
created, “Stem-Cell Researchers Claim Embryo Labs Are Still a Necessity,” points out that there are 
shortcomings in the new techniques. Scientists in the article point out that until the differences of 
induced pluripotent stem cells are remedied, "Human ESCs will be better, even if they are more 
complicated politically.”34 
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A medical journal article published six days later confirmed that there were still significant problems to 
overcome before induced pluripotent stem cells can justifiably be able to replace embryonic research. 
There are still unknowns about how induced pluripotent cells are actually created. Scientists are not 
sure exactly what the four genes used to induce pluripotency do to a cell; there may be other ways to 
reach the same end result.35 Also, as it said in the newspaper article, the risk of teratomas forming is 
potentially greater than with ESCs.
 
An article published in The Boston Globe three months later once again focuses on the therapeutic uses, 
but is more realistic about the immediate potential of the research than newspapers in previous years. 
The article describes advances made by alleviating the symptoms of Parkinson’s disease in mice using 
induced pluripotent stem cells. MIT scientist Rudolph Jaenisch is quoted saying that “These cells are 
more readily available and much less controversial than ESCs. But they seem to have identical 
potential.”
34 
36 
The medical journal referenced justifies the article, coming to the same conclusions as the newspaper. It 
describes the potential of induced pluripotent stem cells and is relatively optimistic, even while pointing 
out the obstacles still standing in the way of full confidence.37 
This is the point that the media has arrived at in the face of the presidential election. Rather than 
exaggerating much like what had been done in the past, both sides of arguments are usually realistically 
presented to show that the political argument is alive.  
Figure 7: Key Information Source for Supporters and Opponents of Stem Cell Research 
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Conclusion 
 
The main argument against ESC research is the fact that destruction of embryos is necessary for the 
research to continue. Political rivals of ESC research point out that there are several equal alternatives. 
Although these alternatives to ESCs, such as iPS cells, MAPCs, and hematopoietic stem cells, show 
characteristics similar to ESCs, the current data does not conclusively show that these alternatives can 
effectively replace ESCs as therapeutics. 
The media has played a large part in informing the public about stem cell research, its developments, 
and its disputes (Table 2; Figure 7). There are some false perceptions of the capabilities of stem cells 
because of early exaggerations made by the media. It is important for the general public to understand 
that although embryonic stem cell research provides the potential for cures of certain diseases, they are 
very far off. More recently, newspaper articles have been specifically based on reports in medical 
journals and tend to deliver more accurate information. Also, influenced by the political and ethical 
rivalry, the media tends to present both sides of every argument, which is more beneficial for readers 
(Figure 8). 
With the proper interpretations of the popular press, readers should be able to make more informed 
decisions about their stances on stem cell research and choose an appropriate presidential candidate. 
This is where the past legislation becomes important. The most important finding of this report shows 
Figure 8: Schematic representation of the interactions between different groups 
that affect embryonic stem cell research. 
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that Obama and McCain have similar views on stem cells, in contrast to the opposing stances of their 
respective political parties (Table 1; Figure 6).  
This means that choosing either candidate to be the next President would be likely to yield the same 
potential for stem cell bills to be signed into laws. Since Obama was elected President, it is expected that 
more bills will be passed through the Senate and House. This will happen because it is less likely that the 
bills will be vetoed such as the two that reached President Bush’s desk. Also expected is the content and 
restrictions that will come along with the bills. Obama will be more willing to pass bills which outline 
specific ethical restrictions such as no creation of embryos for the purpose of destroying them for 
research. The enactment of any further embryonic stem cell legislation will add to the relatively brief, 
but still very eventful history of embryonic stem cell research (Figure 9). 
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 Figure 9: Timeline of Relevant Events in the 2000’s. 
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Appendix 1: Voter’s Pamphlet
Embryonic Stem Cells 
in the Political Arena:
Fact vs. Fiction
A voter’s guide to the issue of stem 
cells in the Presidential Election.
In this guide:
Stem cell debate•	
Pros/cons of embryonic stem cell research•	
Presidential candidates’ •	
voting records on stem 
cell legislation
Wikipedia Commons
Stem Cell Politics
Why the debate?
Supporters of embryonic stem cell research say...
Stem cells may be useful to treat many diseases.*•	
The embryos for experiments would otherwise •	
be discarded as medical waste or frozen for stor-
age in IVF clinics.
Alternative stem cell sources have more limited •	
therapeutic potential
Opponents of embryonic stem cell research say...
Obtaining the stem cells requires the destruction of •	
embryos.
The destruction of one human embryo is too high of a •	
price	to	pay	for	the	benefit	of	another.
Many alternatives are available with therapeutic uses •	
(i.e. adult stem cells from skin, blood, or bone marrow).
Presidential candidates’ voting records
All candidates with voting records have the same amount of support for embryonic stem cells. They all require 
ethical limitations on the research such as:
no creation of embryos for the sole purpose of destruction for cultivation of stem cells.1. 
all cells must come from embryos that will never be placed in a woman’s womb and would otherwise be 2. 
discarded as medical waste.
no monetary compensation may be given to donors of the embryos.3. 
written consent from the donor must be present for any embryo to be accepted as a stem cell source.4. 
* A unique characteristic of embryonic stem cells is that they have the ability to become any cell type in the human body.
For more information about embryonic stem cells, visit stemcells.nih.gov
1 H.R. 810 provides funding for embryonic stem cell research.
2 S. 2754 supports alternatives to embryonic stem cell research and supports research of treatments.
3 S. 5 provides funding for embryonic stem cell research as well as alternatives.
4 S. 30 would put more funding into alternatives to embryonic stem cells, but saying yea does not necessarily mean the candidate opposes embryonic stem cells.
Obama McCain Biden Republican
Party
Democratic
Party
Passage of H.R. 810
Stem Cell Research Enhancement Act 
of 2005
Yea Yea Yea Nay Yea
Passage of S. 2754
Alternative Pluripotent Stem Cell 
Therapies Enhancement Act
Yea Yea Yea Yea Yea
Passage of S. 5
Stem Cell Research Enhancement Act 
of 2007
Yea Yea Yea Nay Yea
Passageof S. 30
Hope Offered through the Principled 
and Ethical Stem Cell Research Act
(HOPE Act)
Nay Yea Yea Yea Nay
4
3
2
1
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Appendix 2: HR 81038 
H. R. 810
One Hundred Ninth Congress
of the
United States of America 
AT THE SECOND SESSION 
Begun and held at the City of Washington on Tuesday, 
the third day of January, two thousand and six 
An Act 
To amend the Public Health Service Act to provide for human embryonic stem 
cell research.
Be it enacted by the Senate and House of Representatives of 
the United States of America in Congress assembled, 
SECTION 1. SHORT TITLE. 
This Act may be cited as the ‘‘Stem Cell Research Enhancement 
Act of 2005’’. 
SEC. 2. HUMAN EMBRYONIC STEM CELL RESEARCH. 
Part H of title IV of the Public Health Service Act (42 U.S.C. 
289 et seq.) is amended by inserting after section 498C the following: 
‘‘SEC. 498D. HUMAN EMBRYONIC STEM CELL RESEARCH. 
‘‘(a) IN GENERAL.—Notwithstanding any other provision of law 
(including any regulation or guidance), the Secretary shall conduct 
and support research that utilizes human embryonic stem cells 
in accordance with this section (regardless of the date on which 
the stem cells were derived from a human embryo). 
‘‘(b) ETHICAL REQUIREMENTS.—Human embryonic stem cells 
shall be eligible for use in any research conducted or supported 
by the Secretary if the cells meet each of the following: 
‘‘(1) The stem cells were derived from human embryos 
that have been donated from in vitro fertilization clinics, were 
created for the purposes of fertility treatment, and were in 
excess of the clinical need of the individuals seeking such 
treatment. 
‘‘(2) Prior to the consideration of embryo donation and 
through consultation with the individuals seeking fertility treat-
ment, it was determined that the embryos would never be 
implanted in a woman and would otherwise be discarded. 
‘‘(3) The individuals seeking fertility treatment donated 
the embryos with written informed consent and without 
receiving any financial or other inducements to make the dona-
tion. 
‘‘(c) GUIDELINES.—Not later than 60 days after the date of 
the enactment of this section, the Secretary, in consultation with 
the Director of NIH, shall issue final guidelines to carry out this 
section. 
‘‘(d) REPORTING REQUIREMENTS.—The Secretary shall annually 
prepare and submit to the appropriate committees of the Congress 
a report describing the activities carried out under this section 
during the preceding fiscal year, and including a description of 
H. R. 810—2
whether and to what extent research under subsection (a) has 
been conducted in accordance with this section.’’.
Speaker of the House of Representatives.
Vice President of the United States and
President of the Senate. 
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Appendix 3: S 275439 
109TH CONGRESS
2D SESSION S. 2754
AN ACT
To derive human pluripotent stem cell lines using techniques
that do not knowingly harm embryos.
Be it enacted by the Senate and House of Representa-1
tives of the United States of America in Congress assembled,2
SECTION 1. SHORT TITLE.3
This Act may be cited as the ‘‘Alternative Pluripotent4
Stem Cell Therapies Enhancement Act’’.5
 †
2
S 2754 ES
SEC. 2. PURPOSES.1
It is the purpose of this Act to—2
(1) intensify research that may result in im-3
proved understanding of or treatments for diseases4
and other adverse health conditions; and5
(2) promote the derivation of pluripotent stem6
cell lines, including from postnatal sources, without7
creating human embryos for research purposes or8
discarding, destroying, or knowingly harming a9
human embryo or fetus.10
SEC. 3. ALTERNATIVE HUMAN PLURIPOTENT STEM CELL11
RESEARCH.12
Part B of title IV of the Public Health Service Act13
(42 U.S.C. 284 et seq.) is amended by inserting after sec-14
tion 498C the following:15
‘‘SEC. 409J. ALTERNATIVE HUMAN PLURIPOTENT STEM16
CELL RESEARCH.17
‘‘(a) IN GENERAL.—In accordance with section 492,18
the Secretary shall conduct and support basic and applied19
research to develop techniques for the isolation, derivation,20
production, or testing of stem cells that, like embryonic21
stem cells, are capable of producing all or almost all of22
the cell types of the developing body and may result in23
improved understanding of or treatments for diseases and24
other adverse health conditions, but are not derived from25
a human embryo.26
 †
3
S 2754 ES
‘‘(b) GUIDELINES.—Not later than 90 days after the1
date of the enactment of this section, the Secretary, after2
consultation with the Director, shall issue final guidelines3
to implement subsection (a), that—4
‘‘(1) provide guidance concerning the next steps5
required for additional research, which shall include6
a determination of the extent to which specific tech-7
niques may require additional basic or animal re-8
search to ensure that any research involving human9
cells using these techniques would clearly be con-10
sistent with the standards established under this sec-11
tion;12
‘‘(2) prioritize research with the greatest poten-13
tial for near-term clinical benefit; and14
‘‘(3) consistent with subsection (a), take into15
account techniques outlined by the President’s Coun-16
cil on Bioethics and any other appropriate tech-17
niques and research.18
‘‘(c) REPORTING REQUIREMENTS.—Not later than19
January 1 of each year, the Secretary shall prepare and20
submit to the appropriate committees of the Congress a21
report describing the activities carried out under this sec-22
tion during the fiscal year, including a description of the23
research conducted under this section.24
 †
4
S 2754 ES
‘‘(d) RULE OF CONSTRUCTION.—Nothing in this sec-1
tion shall be construed to affect any policy, guideline, or2
regulation regarding embryonic stem cell research, human3
cloning by somatic cell nuclear transfer, or any other re-4
search not specifically authorized by this section.5
‘‘(e) DEFINITION.—6
‘‘(1) IN GENERAL.—In this section, the term7
‘human embryo’ shall have the meaning given such8
term in the applicable appropriations Act.9
‘‘(2) APPLICABLE ACT.—For purposes of para-10
graph (1), the term ‘applicable appropriations Act’11
means, with respect to the fiscal year in which re-12
search is to be conducted or supported under this13
section, the Act making appropriations for the De-14
partment of Health and Human Services for such15
fiscal year, except that if the Act for such fiscal year16
does not contain the term referred to in paragraph17
(1), the Act for the previous fiscal year shall be18
deemed to be the applicable appropriations Act.19
‘‘(f) AUTHORIZATION OF APPROPRIATIONS.—There20
is authorized to be appropriated such sums as may be nec-21
 †
5
S 2754 ES
essary for each of fiscal years 2007 through 2009, to carry1
out this section.’’.2
Passed the Senate July 18, 2006.
Attest:
Secretary.
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Appendix 4: S 540 
S. 5
One Hundred Tenth Congress
of the
United States of America
AT THE FIRST SESSION
Begun and held at the City of Washington on Thursday,
the fourth day of January, two thousand and seven
An Act
To amend the Public Health Service Act to provide for human embryonic stem
cell research.
Be it enacted by the Senate and House of Representatives of
the United States of America in Congress assembled,
SECTION 1. SHORT TITLE.
This Act may be cited as the ‘‘Stem Cell Research Enhancement
Act of 2007’’.
SEC. 2. HUMAN EMBRYONIC STEM CELL RESEARCH.
Part H of title IV of the Public Health Service Act (42 U.S.C.
289 et seq.) is amended by inserting after section 498C the following:
‘‘SEC. 498D. HUMAN EMBRYONIC STEM CELL RESEARCH.
‘‘(a) IN GENERAL.—Notwithstanding any other provision of law
(including any regulation or guidance), the Secretary shall conduct
and support research that utilizes human embryonic stem cells
in accordance with this section (regardless of the date on which
the stem cells were derived from a human embryo).
‘‘(b) ETHICAL REQUIREMENTS.—Human embryonic stem cells
shall be eligible for use in any research conducted or supported
by the Secretary if the cells meet each of the following:
‘‘(1) The stem cells were derived from human embryos
that have been donated from in vitro fertilization clinics, were
created for the purposes of fertility treatment, and were in
excess of the clinical need of the individuals seeking such
treatment.
‘‘(2) Prior to the consideration of embryo donation and
through consultation with the individuals seeking fertility treat-
ment, it was determined that the embryos would never be
implanted in a woman and would otherwise be discarded.
‘‘(3) The individuals seeking fertility treatment donated
the embryos with written informed consent and without
receiving any financial or other inducements to make the dona-
tion.
‘‘(c) GUIDELINES.—Not later than 60 days after the date of
the enactment of this section, the Secretary, in consultation with
the Director of NIH, shall issue final guidelines to carry out this
section.
‘‘(d) REPORTING REQUIREMENTS.—The Secretary shall annually
prepare and submit to the appropriate committees of the Congress
a report describing the activities carried out under this section
during the preceding fiscal year, and including a description of
S. 5—2
whether and to what extent research under subsection (a) has
been conducted in accordance with this section.’’.
SEC. 3. ALTERNATIVE HUMAN PLURIPOTENT STEM CELL RESEARCH.
Part H of title IV of the Public Health Service Act (42 U.S.C.
284 et seq.), as amended by section 2, is further amended by
inserting after section 498D the following:
‘‘SEC. 498E. ALTERNATIVE HUMAN PLURIPOTENT STEM CELL
RESEARCH.
‘‘(a) IN GENERAL.—In accordance with section 492, the Secretary
shall conduct and support basic and applied research to develop
techniques for the isolation, derivation, production, or testing of
stem cells that, like embryonic stem cells, are capable of producing
all or almost all of the cell types of the developing body and
may result in improved understanding of or treatments for diseases
and other adverse health conditions, but are not derived from
a human embryo.
‘‘(b) GUIDELINES.—Not later than 90 days after the date of
the enactment of this section, the Secretary, after consultation
with the Director, shall issue final guidelines to implement sub-
section (a), that—
‘‘(1) provide guidance concerning the next steps required
for additional research, which shall include a determination
of the extent to which specific techniques may require addi-
tional basic or animal research to ensure that any research
involving human cells using these techniques would clearly
be consistent with the standards established under this section;
‘‘(2) prioritize research with the greatest potential for near-
term clinical benefit; and
‘‘(3) consistent with subsection (a), take into account tech-
niques outlined by the President’s Council on Bioethics and
any other appropriate techniques and research.
‘‘(c) REPORTING REQUIREMENTS.—Not later than January 1 of
each year, the Secretary shall prepare and submit to the appropriate
committees of the Congress a report describing the activities carried
out under this section during the fiscal year, including a description
of the research conducted under this section.
‘‘(d) RULE OF CONSTRUCTION.—Nothing in this section shall
be construed to affect any policy, guideline, or regulation regarding
embryonic stem cell research, human cloning by somatic cell nuclear
transfer, or any other research not specifically authorized by this
section.
‘‘(e) DEFINITION.—
‘‘(1) IN GENERAL.—In this section, the term ‘human embryo’
shall have the meaning given such term in the applicable
appropriations Act.
‘‘(2) APPLICABLE ACT.—For purposes of paragraph (1), the
term ‘applicable appropriations Act’ means, with respect to
the fiscal year in which research is to be conducted or supported
under this section, the Act making appropriations for the
Department of Health and Human Services for such fiscal
year, except that if the Act for such fiscal year does not contain
the term referred to in paragraph (1), the Act for the previous
fiscal year shall be deemed to be the applicable appropriations
Act.
S. 5—3
‘‘(f) AUTHORIZATION OF APPROPRIATIONS.—There is authorized
to be appropriated such sums as may be necessary for each of
fiscal years 2008 through 2010, to carry out this section.’’.
Speaker of the House of Representatives.
Vice President of the United States and
President of the Senate.
36 
 
Appendix 5: S 3041 
110TH CONGRESS
1ST SESSION S. 30
AN ACT
To intensify research to derive human pluripotent stem cell
lines.
Be it enacted by the Senate and House of Representa-1
tives of the United States of America in Congress assembled,2
SECTION 1. SHORT TITLE.3
This Act may be cited as the ‘‘Hope Offered through4
Principled and Ethical Stem Cell Research Act’’ or the5
‘‘HOPE Act’’.6
 †
2
S 30 ES
SEC. 2. PURPOSES.1
It is the purpose of this Act to—2
(1) intensify research that may result in im-3
proved understanding of or treatments for diseases4
and other adverse health conditions; and5
(2) promote the derivation of pluripotent stem6
cell lines without the creation of human embryos for7
research purposes and without the destruction or8
discarding of, or risk of injury to, a human embryo9
or embryos other than those that are naturally dead.10
SEC. 3. HUMAN PLURIPOTENT STEM CELL RESEARCH.11
Part H of title IV of the Public Health Service Act12
(42 U.S.C. 289 et seq.) is amended by inserting after sec-13
tion 498C the following:14
‘‘SEC. 498D. HUMAN PLURIPOTENT STEM CELL RESEARCH.15
‘‘(a) IN GENERAL.—The Secretary shall conduct and16
support basic and applied research to develop techniques17
for the isolation, derivation, production, or testing of stem18
cells, including pluripotent stem cells that have the flexi-19
bility of embryonic stem cells (whether or not they have20
an embryonic source), that may result in improved under-21
standing of or treatments for diseases and other adverse22
health conditions, provided that the isolation, derivation,23
production, or testing of such cells will not involve—24
‘‘(1) the creation of a human embryo or em-25
bryos for research purposes; or26
 †
3
S 30 ES
‘‘(2) the destruction or discarding of, or risk of1
injury to, a human embryo or embryos other than2
those that are naturally dead.3
‘‘(b) GUIDELINES.—Not later than 90 days after the4
date of the enactment of this section, the Secretary, after5
consultation with the Director of NIH, shall issue final6
guidelines that—7
‘‘(1) provide guidance concerning the next steps8
required for additional research, which shall include9
a determination of the extent to which specific tech-10
niques may require additional animal research to en-11
sure that any research involving human cells using12
these techniques would clearly be consistent with the13
standards established under subsection (a);14
‘‘(2) prioritize research with the greatest poten-15
tial for near-term clinical benefit;16
‘‘(3) consistent with standards established17
under subsection (a), take into account techniques18
outlined by the President’s Council on Bioethics and19
any other appropriate techniques and research; and20
‘‘(4) in the case of research involving stem cells21
from a naturally dead embryo, require assurances22
from grant applicants that no alteration of the tim-23
ing, methods, or procedures used to create, main-24
tain, or intervene in the development of a human25
 †
4
S 30 ES
embryo was made solely for the purpose of deriving1
the stem cells.2
‘‘(c) REPORTING REQUIREMENTS.—Not later than3
January 1 of each year, the Secretary shall prepare and4
submit to the appropriate committees of the Congress a5
report describing the activities carried out under this sec-6
tion during the fiscal year, including a description of the7
research conducted under this section.8
‘‘(d) RULE OF CONSTRUCTION.—Nothing in this sec-9
tion shall be construed as altering the policy in effect on10
the date of enactment of this section regarding the eligi-11
bility of stem cell lines for funding by the National Insti-12
tutes of Health.13
‘‘(e) AUTHORIZATION OF APPROPRIATIONS.—There14
is authorized to be appropriated such sums as may be nec-15
essary to carry out this section.16
‘‘(f) DEFINITIONS.—In this section:17
‘‘(1) NATURALLY DEAD.—The term ‘naturally18
dead’ means having naturally and irreversibly lost19
the capacity for integrated cellular division, growth,20
and differentiation that is characteristic of an orga-21
nism, even if some cells of the former organism may22
be alive in a disorganized state.23
‘‘(2) HUMAN EMBRYO OR EMBRYOS.—The term24
‘human embryo or embryos’ includes any organism,25
 †
5
S 30 ES
not protected as a human subject under part 46 of1
title 45, Code of Federal Regulations, as of the date2
of enactment of this section, that is derived by fer-3
tilization, parthenogenesis, cloning, or any other4
means from one or more human gametes or human5
diploid cells.6
‘‘(3) RISK OF INJURY.—The term ‘risk of in-7
jury’ means subjecting a human embryo or embryos8
to risk of injury or death greater than that allowed9
for research on fetuses in utero under section10
46.204(b) of title 45, Code of Federal Regulations,11
and section 498(b) of this Act.’’.12
SEC. 4. NATIONAL AMNIOTIC AND PLACENTAL STEM CELL13
BANK.14
(a) IN GENERAL.—The Secretary of Health and15
Human Services shall enter into a contract with the Insti-16
tute of Medicine for the conduct of a study to recommend17
an optimal structure for an amniotic and placental stem18
cell bank program and to address pertinent issues to maxi-19
mize the potential of such technology, including collection,20
storage, standards setting, information sharing, distribu-21
tion, reimbursement, research, and outcome measures. In22
conducting such study, the Institute should receive input23
from relevant experts including the existing operators of24
 †
6
S 30 ES
federal tissue bank programs and the biomedical research1
programs within the Department of Defense.2
(b) REPORT.—Not later than 180 days after the date3
of enactment of this Act, the Institute of Medicine shall4
complete the study under subsection (a) and submit to the5
Secretary of Health and Human Services and the appro-6
priate committees of Congress a report on the results of7
such study.8
Passed the Senate April 11, 2007.
Attest:
Secretary.
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Appendix 6: House Document 109-127: Veto to HR 81042 
U.S. GOVERNMENT PRINTING OFFICE
WASHINGTON : 
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49–011 2006 
109th Congress, 2d Session – – – – – – – – – – – – House Document 109–127 
VETO MESSAGE ON H.R. 810 
MESSAGE 
FROM 
THE PRESIDENT OF THE UNITED STATES 
TRANSMITTING 
HIS VETO OF H.R. 810, THE STEM CELL RESEARCH 
ENHANCEMENT ACT OF 2005 
JULY 20, 2006.—Message and accompanying papers referred to the 
Committee on Energy and Commerce and ordered to be printed 
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(1) 
To the House of Representatives: 
I am returning herewith without my approval H.R. 810, the 
‘‘Stem Cell Research Enhancement Act of 2005.’’ 
Like all Americans, I believe our Nation must vigorously pursue 
the tremendous possibilities that science offers to cure disease and 
improve the lives of millions. Yet, as science brings us ever closer 
to unlocking the secrets of human biology, it also offers temptations 
to manipulate human life and violate human dignity. Our con-
science and history as a Nation demand that we resist this tempta-
tion. With the right scientific techniques and the right policies, we 
can achieve scientific progress while living up to our ethical respon-
sibilities. 
In 2001, I set forth a new policy on stem cell research that struck 
a balance between the needs of science and the demands of con-
science. When I took office, there was no Federal funding for 
human embryonic stem cell research. Under the policy I announced 
5 years ago, my Administration became the first to make Federal 
funds available for this research, but only on embryonic stem cell 
lines derived from embryos that had already been destroyed. My 
Administration has made available more than $90 million for re-
search of these lines. This policy has allowed important research to 
go forward and has allowed America to continue to lead the world 
in embryonic stem cell research without encouraging the further 
destruction of living human embryos. 
H.R. 810 would overturn my Administration’s balanced policy on 
embryonic stem cell research. If this bill were to become law, 
American taxpayers for the first time in our history would be com-
pelled to fund the deliberate destruction of human embryos. Cross-
ing this line would be a grave mistake and would needlessly en-
courage a conflict between science and ethics that can only do dam-
age to both and harm our Nation as a whole. 
Advances in research show that stem cell science can progress in 
an ethical way. Since I announced my policy in 2001, my Adminis-
tration has expanded funding of research into stem cells that can 
be drawn from children, adults, and the blood in umbilical cords 
with no harm to the donor, and these stem cells are currently being 
used in medical treatments. Science also offers the hope that we 
may one day enjoy the potential benefits of embryonic stem cells 
without destroying human life. Researchers are investigating new 
techniques that might allow doctors and scientists to produce stem 
cells just as versatile as those derived from human embryos with-
out harming life. We must continue to explore these hopeful alter-
natives, so we can advance the cause of scientific research while 
staying true to the ideals of a decent and humane society. 
I hold to the principle that we can harness the promise of tech-
nology without becoming slaves to technology and ensure that 
science serves the cause of humanity. If we are to find the right 
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2 
ways to advance ethical medical research, we must also be willing 
when necessary to reject the wrong ways. For that reason, I must 
veto this bill 
GEORGE W. BUSH. 
THE WHITE HOUSE, July 19, 2006. 
Æ 
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Appendix 7: Senate Congressional Record S8060-S8061: Veto to S 543 
CONGRESSIONAL RECORD — SENATES8060 June 20, 2007 
I am proud to also recognize the 
many accomplishments of Glazer ele-
mentary students, which is undoubt-
edly the direct result of the hard work 
and dedication of its students, faculty 
and staff. Glazer was recently selected 
as a Leadership School by the Schools 
of the 21st Century and enjoys the dis-
tinction of being awarded the $100,000 
Skillman Improvement Grant, the 
highest award among six elementary 
schools included in the 2007 high per-
forming category out of 300 Detroit ele-
mentary schools. This grant is ex-
pected to help fund several worthwhile 
initiatives, including a GED certificate 
program and the purchase of additional 
computers to assist parents of Glazer 
students who have not completed high 
school. 
The principal of B. Benedict Glazer 
Elementary School, Florene 
McMurtry, has served the Detroit Pub-
lic School system in various positions 
for 35 years. Her passion for education 
is illustrated by the many notable suc-
cesses she has enjoyed throughout her 
career as an educator. An example of 
her innovative approach to education 
was the partnership she helped form 
between Glazer Elementary School and 
Temple Beth El in 1998 to provide fi-
nancial resources and tutors for stu-
dents through the Glazer Elementary 
Ada S. and Rabbi B. Benedict Glazer 
Memorial Fund. Mrs. McMurtry also 
established the tradition of presenting 
dictionaries as the Glazer Memorial 
Prize to honor the most outstanding 
boy and girl student for Class Day. In 
2001, Mrs. McMurtry established the 
InsideOut Literary Arts Project at 
Glazer with a writer-in-residence who 
integrates creative writing and drama 
in the school curriculum and publishes 
the students’ work. To date, seven po-
etry books have been written and pub-
lished. 
Mrs. McMurtry has proven herself to 
be a devoted educator. Through her 
dedicated leadership and the many pro-
grams she has initiated and led, she 
has managed to increase parental in-
volvement in school, student access to 
resources, and has served as a liaison 
between the students and the commu-
nity. In addition, Mrs. McMurtry has 
received many accolades over the years 
in recognition of her outstanding serv-
ice, including the Principal of the Year 
Art Award in 1996 and 2001, the Distin-
guished Service Award, City of Detroit 
in 1985 and she was a finalist for Michi-
gan Teacher of the Year in 1984–1985. 
I know my colleagues in the Senate 
join me in recognizing B. Benedict 
Glazer Elementary School on its 40th 
anniversary and its principal, Florene 
McMurtry, on her impressive record of 
service to the Detroit Public School 
system.∑ 
f 
HONORING GEIGER BROTHERS 
∑ Ms. SNOWE. Mr. President, today I 
recognize an outstanding, family- 
owned small business from my home 
State of Maine that recently received 
the Gannett Family Business of the 
Year Award from the University of 
Southern Maine’s Institute for Family- 
Owned Business. A promotional prod-
ucts distributor, Geiger Brothers of 
Lewiston has been in operation since 
1878. Incredibly, the Geiger family has 
been in charge of the business for the 
entire time—a total of four generation. 
Geiger Brothers was originally found-
ed in Newark, NJ, with a staff of four, 
two of whom were Geiger brothers. 
Since then, Geiger Brothers has under-
gone dramatic transformations, mov-
ing to Maine over half a century ago, 
and expanding to 500 employees be-
tween the Lewiston office and several 
field offices. While the Geiger name 
may not jump out at people from out-
side of Maine, the name ‘‘Farmers’ Al-
manac’’ is universally known. Pub-
lished yearly, the ‘‘Farmers’ Almanac’’ 
is famous for its weather forecasts, 
gardening tips, and recipe suggestions. 
It is a source of great pride for my 
home State of Maine that Geiger 
Brothers publishes the ‘‘Farmers’ Al-
manac.’’ 
It is no surprise that Geiger Brothers 
has won the Gannett Family Business 
of the Year Award. In fact, there is no 
lack of accomplishment or recognition 
in Geiger’s history. The recipient of 
the Margaret Chase Smith Maine Qual-
ity Award, the FedEx Gold Level Sup-
plier, and the Maine State Chamber of 
Commerce Maine Investors Award, 
Geiger’s list of commendations re-
cently grew to include the Advertising 
Specialty Institute’s Family Business 
of the Year and a 2006 Best Places To 
Work In Maine award. 
In addition to publishing the world- 
renowned ‘‘Farmers’ Almanac,’’ Geiger 
Brothers has consistently lived by a 
philosophy of community service. 
When, in 1988, the company ‘‘adopted’’ 
the Montello Elementary School in 
Lewiston, then-President George H.W. 
Bush awarded them with a ‘‘Point of 
Light’’ in celebration of their service 
and volunteerism. Since then, Geiger 
Brothers has continued to organize 
similar partnerships across Maine, and 
the company’s employees have donated 
their time to worthwhile causes all 
across the Lewiston-Auburn area. In 
addition, employees live by ‘‘The Gei-
ger Way,’’ a set of values focused on re-
spect for all involved in the business, 
from employees to clients and every-
one in between. The generous and be-
nevolent spirit of Geiger Brothers is as-
suredly a shining example to all small 
businesses. 
Congratulations to Gene Geiger, CEO 
and president; to Peter Geiger, execu-
tive vice president; and to all of Geiger 
Brothers’ accomplished employees on 
their most recent honor, and all of the 
awards they have received. It is no 
wonder that Geiger Brothers has been 
recognized so consistently throughout 
the years with their dedication and 
willingness to serve. I wish them con-
tinued success and many more editions 
of the ‘‘Farmers’ Almanac.’’∑ 
REPORT OF THE VETO OF S. 5, 
THE STEM CELL RESEARCH EN-
HANCEMENT ACT OF 2007—PM 18 
The PRESIDING OFFICER laid be-
fore the Senate the following message 
from the President of the United 
States, together with an accompanying 
report; which was ordered to be held at 
the desk: 
To the Senate of the United States: 
I am returning herewith without my 
approval S. 5, the ‘‘Stem Cell Research 
Enhancement Act of 2007.’’ 
Once again, the Congress has sent me 
legislation that would compel Amer-
ican taxpayers, for the first time in our 
history, to support the deliberate de-
struction of human embryos. 
In 2001, I announced a policy to ad-
vance stem cell research in a way that 
is ambitious, ethical, and effective. I 
became the first President to make 
Federal funds available for embryonic 
stem cell research, and my policy did 
this in ways that would not encourage 
the destruction of embryos. Since then, 
my Administration has made more 
than $130 million available for research 
on stem cell lines derived from em-
bryos that had already been destroyed. 
We have also provided more than $3 bil-
lion for research on all forms of stem 
cells, including those from adult and 
other non-embryonic sources. 
This careful approach is producing 
results. It has contributed to proven 
therapeutic treatments in thousands of 
patients with many different diseases. 
And it is opening the prospect of new 
discoveries that could transform lives. 
Researchers are now developing prom-
ising new techniques that offer the po-
tential to produce pluripotent stem 
cells, without having to destroy human 
life—for example, by reprogramming 
adult cells to make them function like 
stem cells. 
Technical innovation in this difficult 
area is opening up new possibilities for 
progress without conflict or ethical 
controversy. Researchers pursuing 
these kinds of ethically responsible ad-
vances deserve support, and there is 
legislation in the Congress to give 
them that support. Bills supporting al-
ternative research methods achieved 
majority support last year in both the 
House and the Senate. Earlier this 
spring another bill supporting alter-
native research won overwhelming ma-
jority support in the Senate, and I call 
on House leaders to pass similar legis-
lation that would authorize additional 
funds for ethical stem cell research. We 
cannot lose the opportunity to conduct 
research that would give hope to those 
suffering from terrible diseases and 
help move our Nation beyond the con-
troversies over embryo destruction. I 
invite policymakers and scientists to 
come together to solve medical prob-
lems without compromising either the 
high aims of science or the sanctity of 
human life. 
S. 5, like the bill I vetoed last year, 
would overturn today’s carefully bal-
anced policy on stem cell research. 
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Compelling American taxpayers to sup-
port the deliberate destruction of 
human embryos would be a grave mis-
take. I will not allow our Nation to 
cross this moral line. For that reason, 
I must veto this bill. 
GEORGE W. BUSH.
THE WHITE HOUSE, June 20, 2007. 
f 
MESSAGE FROM THE HOUSE 
ENROLLED BILLS SIGNED 
The President Pro Tempore (Mr. 
BYRD) announced that on today, June 
20, 2007, he had signed the following en-
rolled bills, which were previously 
signed by the Speaker of the House: 
H.R. 57. An act to repeal certain sections of 
the Act of May 26, 1936, pertaining to the 
Virgin Islands. 
H.R. 692. An act to amend title 4, United 
States Code, to authorize the Governor of a 
State, territory, or possession of the United 
States to order that the National flag be 
flown at half-staff in that State, territory, or 
possession in the event of the death of a 
member of the Armed Forces from that 
State, territory, or possession who dies while 
serving on active duty. 
f 
MEASURES READ THE FIRST TIME 
The following bill was read the first 
time: 
H.R. 2366. An act to reauthorize the vet-
erans entrepreneurial development programs 
of the Small Business Administration, and 
for other purposes. 
f 
REPORTS OF COMMITTEES 
The following reports of committees 
were submitted: 
By Mr. LIEBERMAN, from the Committee 
on Homeland Security and Governmental Af-
fairs, without amendment: 
H.R. 1255. A bill to amend chapter 22 of 
title 44, United States Code, popularly 
known as the Presidential Records Act, to 
establish procedures for the consideration of 
claims of constitutionally based privilege 
against disclosure of Presidential records. 
By Mr. LEAHY, from the Committee on 
the Judiciary, with an amendment in the na-
ture of a substitute and an amendment to 
the title: 
S. 535. A bill to establish an Unsolved 
Crimes Section in the Civil Rights Division 
of the Department of Justice, and an Un-
solved Civil Rights Crime Investigative Of-
fice in the Civil Rights Unit of the Federal 
Bureau of Investigation, and for other pur-
poses. 
By Mr. LIEBERMAN, from the Committee 
on Homeland Security and Governmental Af-
fairs, without amendment: 
S. 886. A bill to amend chapter 22 of title 
44, United States Code, popularly known as 
the Presidential Records Act, to establish 
procedures for the consideration of claims of 
constitutionally based privilege against dis-
closure of Presidential records. 
f 
EXECUTIVE REPORTS OF 
COMMITTEES 
The following executive reports of 
nominations were submitted: 
By Mr. KENNEDY for the Committee on 
Health, Education, Labor, and Pensions. 
*Marylyn Andrea Howe, of Massachusetts, 
to be a Member of the National Council on 
Disability for a term expiring September 17, 
2008. 
*Lonnie C. Moore, of Kansas, to be a Mem-
ber of the National Council on Disability for 
a term expiring September 17, 2008. 
*Kerri Layne Briggs, of Virginia, to be As-
sistant Secretary for Elementary and Sec-
ondary Education, Department of Education. 
*Jerome F. Kever, of Illinois, to be a Mem-
ber of the Railroad Retirement Board for a 
term expiring August 28, 2008. 
*Michael Schwartz, of Illinois to be a Mem-
ber of the Railroad Retirement Board for a 
term expiring August 28, 2012. 
*Virgil M. Speakman, Jr., of Ohio, to be a 
Member of the Railroad Retirement Board 
for a term expiring August 28, 2009. 
*Nomination was reported with rec-
ommendation that it be confirmed sub-
ject to the nominee’s commitment to 
respond to requests to appear and tes-
tify before any duly constituted com-
mittee of the Senate. 
f 
INTRODUCTION OF BILLS AND 
JOINT RESOLUTIONS 
The following bills and joint resolu-
tions were introduced, read the first 
and second times by unanimous con-
sent, and referred as indicated: 
By Mr. FEINGOLD (for himself, Mr. 
KOHL, Mr. KENNEDY, and Mr. BROWN): 
S. 1664. A bill to require the Secretary of 
the Treasury to mint coins in commemora-
tion of Robert M. La Follette, Sr., in rec-
ognition of his important contributions to 
the Progressive movement, the State of Wis-
consin, and the United States; to the Com-
mittee on Banking, Housing, and Urban Af-
fairs. 
By Mr. FEINGOLD (for himself, Mr. 
KOHL, Mr. KENNEDY, and Mr. BROWN): 
S. 1665. A bill to authorize the President to 
posthumously award a gold medal on behalf 
of Congress to Robert M. La Follette, Sr., in 
recognition of his important contributions 
to the Progressive movement, the State of 
Wisconsin, and the United States; to the 
Committee on Banking, Housing, and Urban 
Affairs. 
By Mr. BAUCUS (for himself and Mr. 
GRASSLEY): 
S. 1666. A bill to amend title II of the So-
cial Security Act to improve the process for 
congressional consideration of international 
social security agreements; to the Com-
mittee on Finance. 
By Mr. CARPER (for himself and Mr. 
COBURN): 
S. 1667. A bill to establish a pilot program 
for the expedited disposal of Federal real 
property; to the Committee on Homeland Se-
curity and Governmental Affairs. 
By Mr. DODD (for himself and Ms. 
LANDRIEU): 
S. 1668. A bill to assist in providing afford-
able housing to those affected by the 2005 
hurricanes; to the Committee on Banking, 
Housing, and Urban Affairs. 
By Ms. STABENOW (for herself, Mr. 
BINGAMAN, Mr. LEVIN, Mr. SALAZAR, 
Mr. DURBIN, Mr. OBAMA, and Mr. 
KERRY): 
S. 1669. A bill to amend titles XIX and XXI 
of the Social Security Act to ensure pay-
ment under Medicaid and the State Chil-
dren’s Health Insurance Program (SCHIP) 
for covered items and services furnished by 
school-based health clinics; to the Com-
mittee on Finance. 
By Ms. SNOWE: 
S. 1670. A bill to amend title 10, United 
States Code, to improve the management of 
medical care for members of the Armed 
Forces, to improve the speed and efficiency 
of the physical disability evaluation system 
of the Department of Defense, and for other 
purposes; to the Committee on Armed Serv-
ices. 
By Mr. KERRY (for himself and Ms. 
SNOWE): 
S. 1671. A bill to reauthorize and improve 
the entrepreneurial development programs 
of the Small Business Administration, and 
for other purposes; to the Committee on 
Small Business and Entrepreneurship. 
f 
SUBMISSION OF CONCURRENT AND 
SENATE RESOLUTIONS 
The following concurrent resolutions 
and Senate resolutions were read, and 
referred (or acted upon), as indicated: 
By Mr. SMITH (for himself and Mr. 
CONRAD): 
S. Res. 240. A resolution designating Octo-
ber 21 through October 27, 2007, as ‘‘National 
Save for Retirement Week’’; to the Com-
mittee on the Judiciary. 
By Mr. BROWN: 
S. Res. 241. A resolution expressing the 
sense of the Senate that the United States 
should reaffirm the commitments of the 
United States to the 2001 Doha Declaration 
on the TRIPS Agreement and Public Health 
and to pursuing trade policies that promote 
access to affordable medicines; to the Com-
mittee on Finance. 
By Mrs. MURRAY (for herself, Mr. STE-
VENS, Ms. SNOWE, Ms. MIKULSKI, Ms. 
CANTWELL, Mr. OBAMA, Mr. KENNEDY, 
Ms. STABENOW, Mr. KERRY, Mr. DODD, 
Mr. DURBIN, Mr. FEINGOLD, Mr. BAYH, 
Mr. MENENDEZ, Mrs. CLINTON, Mrs. 
FEINSTEIN, Mr. INOUYE, Mr. BAUCUS, 
Mr. AKAKA, Mr. SMITH, and Mrs. 
BOXER): 
S. Res. 242. A resolution celebrating the ac-
complishments of title IX of the Education 
Amendments of 1972, also known as the 
Patsy Takemoto Mink Equal Opportunity in 
Education Act, and recognizing the need to 
continue pursuing the goal of educational 
opportunities for women and girls; consid-
ered and agreed to. 
By Mr. LAUTENBERG (for himself, 
Mr. MARTINEZ, Mr. LIEBERMAN, Mrs. 
DOLE, Ms. STABENOW, Mr. STEVENS, 
Mr. BIDEN, Mr. BURR, Mr. LEVIN, Ms. 
MURKOWSKI, Mr. KERRY, Ms. SNOWE, 
Ms. LANDRIEU, Mr. LOTT, Mr. MENEN-
DEZ, Mr. DURBIN, Mr. WYDEN, Mr. 
FEINGOLD, Mr. CARDIN, Mr. CARPER, 
and Ms. CANTWELL): 
S. Res. 243. A resolution supporting the 
goals and ideals of National Clean Beaches 
Week and the considerable value of beaches 
and their role in American culture; consid-
ered and agreed to. 
By Mr. PRYOR (for himself, Mr. 
SUNUNU, Mrs. DOLE, Mr. LUGAR, Ms. 
LANDRIEU, Ms. MURKOWSKI, and Mr. 
ISAKSON): 
S. Res. 244. A resolution designating June 
2007 as National Safety Month; considered 
and agreed to. 
By Mr. KYL (for himself and Mr. 
MCCAIN): 
S. Res. 245. A resolution congratulating the 
University of Arizona Wildcats for winning 
the 2007 NCAA Division I Softball Champion-
ship; considered and agreed to. 
By Mrs. HUTCHISON (for herself and 
Mr. CORNYN): 
S. Res. 246. A resolution congratulating the 
San Antonio Spurs for winning the National 
Basketball Association Championship; con-
sidered and agreed to. 
By Ms. CANTWELL (for herself and 
Mrs. MURRAY): 
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